Company intelligence / Profile preview

Trygg Pharma

Ownership: Private
Employees: ~74
Development stage: Phase 3

Overview

Trygg Pharma produces omega-3 fatty acids for pharmaceutical applications. Their product Omega-3-acid ethyl esters has been approved in the United States since November 10, 2004, for the treatment of hypertriglyceridemia[1][4].

Therapeutic areas: Metabolic Disorders
Modalities: Omega-3 fatty acids
Industry: Biotech

Drug pipeline

1 asset

CaPre

Phase 3

Indications: Severe hypertriglyceridemia, Hypertriglyceridemia

Beyond the preview

Go deeper on Trygg Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trygg Pharma.

Explore the full profile